Top

Published in:

01-05-2010 | Epidemiology

GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis

Authors: Theodoros N. Sergentanis, Konstantinos P. Economopoulos

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk. Regarding GSTT1 and GSTP1 polymorphisms, studies remain controversial and no recent meta-analysis has appeared. This meta-analysis aims to examine whether GSTT1 and GSTP1 polymorphisms are associated with breast cancer risk. Separate analyses were performed on Chinese and non-Chinese populations, in an attempt to investigate race-specific effects. Eligible articles were identified by a search of MEDLINE bibliographic database for the period up to August 2009. Regarding GSTT1 null/present genotype, 41 case–control studies were eligible (16,589 breast cancer cases and 19,995 controls); 30 case–control studies were eligible for GSTP1 Ile105Val (16,908 cases and 20,016 controls). Pooled odds ratios (ORs) were appropriately derived from fixed-effects or random-effects models. At the overall analysis, the null GSTT1 genotype was associated with elevated breast cancer risk (pooled OR = 1.114, 95% CI: 1.035–1.199, random effects). However, the association seemed confined to non-Chinese populations (33 studies, pooled OR = 1.128, 95% CI: 1.042–1.221, random effects), given that the association was not significant in the subset of Chinese studies (eight studies, pooled OR = 1.061, 95% CI: 0.875–1.286, random effects). Regarding GSTP1 Ile105Val, no statistically significant associations were detected in non-Chinese populations (25 studies). On the other hand, the GG genotype was associated with increased breast cancer risk in Chinese populations (five studies, pooled OR = 1.297, 95% CI: 1.023–1.645, fixed effects); accordingly, the recessive model yielded statistically significant results (pooled OR = 1.273, 95% CI: 1.006–1.610, fixed effects). In conclusion, polymorphisms of both GSTT1 and GSTP1 genes seem associated with elevated breast cancer risk in a race-specific manner. Given the small number of Chinese studies, the finding on GSTP1 Ile105Val merits further investigation.

Hengstler JG, Arand M, Herrero ME, Oesch F (1998) Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154:47–85PubMed

Kano T, Sakai M, Muramatsu M (1987) Structure and expression of a human class pi glutathione S-transferase messenger RNA. Cancer Res 47:5626–5630PubMed

Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM (2009) A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J 23:2274–2287CrossRefPubMed

Vogl FD, Taioli E, Maugard C, Zheng W, Pinto LF, Ambrosone C, Parl FF, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P et al (2004) Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 13:1473–1479PubMed

Egan KM, Cai Q, Shu XO, Jin F, Zhu TL, Dai Q, Gao YT, Zheng W (2004) Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers Prev 13:197–204CrossRefPubMed

Park SK, Yim DS, Yoon KS, Choi IM, Choi JY, Yoo KY, Noh DY, Choe KJ, Ahn SH, Hirvonen A et al (2004) Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res Treat 88:55–62CrossRefPubMed

Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, Roth Z, Soucek P (2004) Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 12:848–854CrossRefPubMed

Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N (2005) The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26:1457–1464CrossRefPubMed

Chacko P, Joseph T, Mathew BS, Rajan B, Pillai MR (2005) Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res 581:153–163PubMed

10.

Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, Wu PE, Shen CY (2005) Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 113:345–353CrossRefPubMed

11.

Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W (2006) Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan. Breast 15:754–761CrossRefPubMed

12.

Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bohn M, Erikstein B, Helland A, Borresen-Dale AL, Fossa SD (2007) Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 67:1163–1171PubMed

13.

Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnaes GI, Lemmon G, Berg M, Geisler S, Moore JH, Lonning PE et al (2007) ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics 17:127–136CrossRefPubMed

14.

Spurdle AB, Chang JH, Byrnes GB, Chen X, Dite GS, McCredie MR, Giles GG, Southey MC, Chenevix-Trench G, Hopper JL (2007) A systematic approach to analysing gene–gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:769–774CrossRefPubMed

15.

Steck SE, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB, Neugut AI, Santella RM, Gammon MD (2007) Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk. Carcinogenesis 28:1954–1959CrossRefPubMed

16.

Chang YL, Li J, Yao SQ, Hu WN, Jiang SF, Guo Z, Yang L, Li DD, Li YM, Liu Y (2008) A case–control study on serum organochlorines residues, genetic polymorphisms of glutathione S-transferase T1 and the risks of breast cancer. Zhonghua Liu Xing Bing Xue Za Zhi 29:763–766PubMed

17.

Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, Peretz T, Eeles RA (2008) Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer 98:2006–2010CrossRefPubMed

18.

Li JY, Long QM, Tao P, Hu R, Li H, Lei FM, Zhou WD, Li SF (2008) Using MSR model to analyze the impact of gene–gene interaction with related to the genetic polymorphism of metabolism enzymes on the risk of breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 39:780–783 See also 787PubMed

19.

Morais LM, Cardoso Filho C, Lourenco GJ, Shinzato JY, Zeferino LC, Lima CS, Gurgel MS (2008) Polymorphisms GSTM1 and GSTT1 and sporadic breast cancer mammographic features. Rev Assoc Med Bras 54:61–66CrossRefPubMed

20.

Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy NK (2008) TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87CrossRefPubMed

21.

Syamala VS, Sreeja L, Syamala V, Raveendran PB, Balakrishnan R, Kuttan R, Ankathil R (2008) Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival. Fam Cancer 7:213–220CrossRefPubMed

22.

Torresan C, Oliveira MM, Torrezan GT, de Oliveira SF, Abuazar CS, Losi-Guembarovski R, Lima RS, Urban CA, Cavalli IJ, Ribeiro EM (2008) Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med 8:65–71CrossRefPubMed

23.

Unlu A, Ates NA, Tamer L, Ates C (2008) Relation of glutathione S-transferase T1, M1 and P1 genotypes and breast cancer risk. Cell Biochem Funct 26:643–647CrossRefPubMed

24.

Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, Allen GO, Rubin P, Sherrill GB, Shaw CS et al (2008) Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 19:1311–1321PubMed

25.

The MARIE-GENICA Consortium (2009) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat. doi:10.1007/s10549-009-0407-0

26.

McCarty KM, Santella RM, Steck SE, Cleveland RJ, Ahn J, Ambrosone CB, North K, Sagiv SK, Eng SM, Teitelbaum SL et al (2009) PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk. Environ Health Perspect 117:552–558PubMed

27.

Reding KW, Weiss NS, Chen C, Li CI, Carlson CS, Wilkerson HW, Farin FM, Thummel KE, Daling JR, Malone KE (2009) Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18:1461–1467CrossRefPubMed

28.

Saxena A, Dhillon VS, Raish M, Asim M, Rehman S, Shukla NK, Deo SV, Ara A, Husain SA (2009) Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population. Breast Cancer Res Treat 115:537–543CrossRefPubMed

29.

Kim SU, Lee KM, Park SK, Yoo KY, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kang D (2004) Genetic polymorphism of glutathione S-transferase P1 and breast cancer risk. J Biochem Mol Biol 37:582–585PubMed

30.

Lee SA, Fowke JH, Lu W, Ye C, Zheng Y, Cai Q, Gu K, Gao YT, Shu XO, Zheng W (2008) Cruciferous vegetables, the GSTP1 Ile105Val genetic polymorphism, and breast cancer risk. Am J Clin Nutr 87:753–760PubMed

31.

Sakoda LC, Blackston CR, Xue K, Doherty JA, Ray RM, Lin MG, Stalsberg H, Gao DL, Feng Z, Thomas DB et al (2008) Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res Treat 109:143–155CrossRefPubMed

32.

Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crino L, Barberini F, Rulli A (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case–control study. BMC Cancer 9:115CrossRefPubMed

33.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMed

34.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed

35.

Zheng T, Holford TR, Zahm SH, Owens PH, Boyle P, Zhang Y, Zhang B, Wise JP Sr, Stephenson LP, Ali-Osman F (2003) Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk. Br J Cancer 88:58–62CrossRefPubMed

36.

Lee KM, Park SK, Kim SU, Doll MA, Yoo KY, Ahn SH, Noh DY, Hirvonen A, Hein DW, Kang D (2003) N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett 196:179–186CrossRefPubMed

37.

Park SK, Yoo KY, Lee SJ, Kim SU, Ahn SH, Noh DY, Choe KJ, Strickland PT, Hirvonen A, Kang D (2000) Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics 10:301–309CrossRefPubMed

38.

Park SK, Kang D, Noh DY, Lee KM, Kim SU, Choi JY, Choi IM, Ahn SH, Choe KJ, Hirvonen A et al (2003) Reproductive factors, glutathione S-transferase M1 and T1 genetic polymorphism and breast cancer risk. Breast Cancer Res Treat 78:89–96CrossRefPubMed

39.

van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Ocke M, Bueno de Mesquita HB (2004) GSTM1 null genotype, red meat consumption and breast cancer risk (The Netherlands). Cancer Causes Control 15:295–303CrossRefPubMed

40.

Gago-Dominguez M, Castelao JE, Sun CL, Van Den Berg D, Koh WP, Lee HP, Yu MC (2004) Marine n-3 fatty acid intake, glutathione S-transferase polymorphisms and breast cancer risk in post-menopausal Chinese women in Singapore. Carcinogenesis 25:2143–2147CrossRefPubMed

41.

Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, Zheng W (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58CrossRefPubMed

42.

Samson M, Swaminathan R, Rama R, Sridevi V, Nancy KN, Rajkumar T (2007) Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India. Asian Pac J Cancer Prev 8:253–257PubMed

43.

Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M et al (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137–149CrossRefPubMed

44.

Zheng T, Holford TR, Zahm SH, Owens PH, Boyle P, Zhang Y, Wise JP Sr, Stephenson LP, Ali-Osman F (2002) Cigarette smoking, glutathione-S-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States). Cancer Causes Control 13:637–645CrossRefPubMed

45.

van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, Bueno de Mesquita HB (2003) NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13:399–407CrossRefPubMed

46.

Nedelcheva Kristensen V, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM, Borresen-Dale AL (1998) Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 8:441–447CrossRefPubMed

47.

Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621–5624PubMed

48.

Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61:7130–7135PubMed

49.

van der Hel OL, Bueno-de-Mesquita HB, van Gils CH, Roest M, Slothouber B, Grobbee DE, Peeters PH (2005) Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands). Cancer Causes Control 16:675–681CrossRefPubMed

50.

Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Case LD, Lin HY, Knight SN, Perrier ND, Rubin P, Sherrill GB et al (2008) Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Mol Carcinog 47:88–99CrossRefPubMed

51.

Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854PubMed

52.

Sgambato A, Campisi B, Zupa A, Bochicchio A, Romano G, Tartarone A, Galasso R, Traficante A, Cittadini A (2002) Glutathione S-transferase (GST) polymorphisms as risk factors for cancer in a highly homogeneous population from southern Italy. Anticancer Res 22:3647–3652PubMed

53.

Mitrunen K, Kataja V, Eskelinen M, Kosma VM, Kang D, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2002) Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics 12:67–72CrossRefPubMed

54.

Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF (2003) Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103:810–814CrossRefPubMed

55.

Khedhaier A, Remadi S, Corbex M, Ahmed SB, Bouaouina N, Mestiri S, Azaiez R, Helal AN, Chouchane L (2003) Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br J Cancer 89:1502–1507CrossRefPubMed

56.

de Amorim L, Rossini A, Mendonca G, Lotsch P, de Almeida Simao T, de Moura Gallo C, Pinto L (2002) CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women. Cancer Lett 181:179–186CrossRef

57.

Matheson MC, Stevenson T, Akbarzadeh S, Propert DN (2002) GSTT1 null genotype increases risk of premenopausal breast cancer. Cancer Lett 181:73–79CrossRefPubMed

58.

Zheng W, Wen WQ, Gustafson DR, Gross M, Cerhan JR, Folsom AR (2002) GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 74:9–16CrossRefPubMed

59.

Wu FY, Lee YJ, Chen DR, Kuo HW (2002) Association of DNA–protein crosslinks and breast cancer. Mutat Res 501:69–78PubMed

60.

Zhao M, Lewis R, Gustafson DR, Wen WQ, Cerhan JR, Zheng W (2001) No apparent association of GSTP1 A(313)G polymorphism with breast cancer risk among postmenopausal Iowa women. Cancer Epidemiol Biomarkers Prev 10:1301–1302PubMed

61.

Xiong P, Bondy ML, Li D, Shen H, Wang LE, Singletary SE, Spitz MR, Wei Q (2001) Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case–control study. Cancer Res 61:8465–8469PubMed

62.

Gudmundsdottir K, Tryggvadottir L, Eyfjord JE (2001) GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 10:1169–1173PubMed

63.

Dialyna IA, Arvanitis DA, Spandidos DA (2001) Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer. Int J Mol Med 8:79–87PubMed

64.

Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D (2001) Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 92:220–225CrossRefPubMed

65.

Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2001) Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 10:229–236PubMed

66.

Maugard CM, Charrier J, Pitard A, Campion L, Akande O, Pleasants L, Ali-Osman F (2001) Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. Int J Cancer 91:334–339CrossRefPubMed

67.

Millikan R, Pittman G, Tse CK, Savitz DA, Newman B, Bell D (2000) Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomarkers Prev 9:567–573PubMed

68.

Curran JE, Weinstein SR, Griffiths LR (2000) Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett 153:113–120CrossRefPubMed

69.

Garcia-Closas M, Kelsey KT, Hankinson SE, Spiegelman D, Springer K, Willett WC, Speizer FE, Hunter DJ (1999) Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 91:1960–1964CrossRefPubMed

70.

Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Watson M, Comstock GW, Bell D (1998) Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 90:512–518CrossRefPubMed

71.

Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF (1998) Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 58:65–70PubMed

72.

Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18:641–644CrossRefPubMed

73.

Raimondi S, Paracchini V, Autrup H, Barros-Dios JM, Benhamou S, Boffetta P, Cote ML, Dialyna IA, Dolzan V, Filiberti R et al (2006) Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol 164:1027–1042CrossRefPubMed

74.

Saadat M (2006) Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci 97:505–509CrossRefPubMed

Title: GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis
Authors: Theodoros N. Sergentanis
Konstantinos P. Economopoulos
Publication date: 01-05-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0520-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family

Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations

IGF-I during primiparous pregnancy and maternal risk of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer